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Background: Atypical antipsychotics are increasingly used in the treatment of a broad spectrum 
of psychiatric disorders. There is evidence that in addition to treating the positive and nega-
tive symptoms of schizophrenia, as well as mania in bipolar disorder, these agents may have a 
potential role to play in the treatment of depressive disorders. In the following article we review 
the literature regarding the role of atypical antipsychotics, and speciﬁ  cally, quetiapine, in the 
treatment of major depressive disorder.
Materials and methods: In March 2007 the authors performed a Medline search (English-
language) using the keywords quetiapine and depression, revealing a total of 47 articles 
published. We also looked for cross-references in the published articles, obtained data-on-ﬁ  le 
from AstraZeneca Pharmaceutical L.P., and included abstracts presented at conferences and 
recent meetings.
Results: From our review we found that there is increasing literature supporting the efﬁ  cacy 
of add-on quetiapine in the treatment of major depressive disorder.
Conclusion: There is a need, however, for further well-designed, adequately powered, 
randomized, controlled trials to conﬁ  rm this ﬁ  nding, speciﬁ  cally in unipolar depression.
Keywords: depression, adjunctive treatment, atypical antipsychotics, quetiapine
Introduction
Major depressive disorder (MDD) is a serious, debilitating illness that affects persons 
of all ages, races, and socioeconomic backgrounds. MDD occurs in up to one in eight 
individuals during their lifetime, making it one of the most prevalent of all medical 
illnesses. According to the Diagnostic and Statistical Manual-Fourth Edition Text 
Revision (DSM-IV TR) (American Psychiatric Association 2000), the point prevalence 
rates for MDD are approximately 2.3%–3.2% in men and 4.5%–9.3% in women, 
with a lifetime risk for developing an episode of 7%–12% for men and 20%–25% for 
women. Furthermore, depression currently ranks fourth for disability adjusted life years 
worldwide and is projected to be the second leading cause of disability worldwide by 
2020 (World Health Organization 2001).
Unfortunately, although antidepressants are effective in the treatment of MDD, 
many patients do not achieve the desired goal of full remission (ie, absence of symp-
toms and return to full premorbid functioning) even with antidepressant trials at 
optimal doses and of adequate duration. The number of patients achieving symptom 
remission to initial antidepressant treatment is no more than 35% among all patients 
treated, with the remaining requiring at least two or more steps in pharmacotherapy 
(Rush et al 2004, 2006).
Treatment-resistant depression (TRD), depression that does not remit after one 
or more adequately delivered treatments (Souery et al 1999; Rush et al 2004), is a Neuropsychiatric Disease and Treatment 2007:3(6) 856
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major and increasing public health burden due to its high 
prevalence, chronic and recurrent course, substantial morbid-
ity, and signiﬁ  cant direct and indirect costs (Greenberg et al 
2003; Rush et al 2004, 2006). Patients with TRD are the most 
impaired and disabled of all patients with MDD (Murray and 
Lopez 1996; Greden 2001; Keller 2005), with psychosocial 
dysfunction contributing to treatment resistance (Papakostas 
et al 2004). Furthermore, treatment resistance may increase 
with increasing number of episodes, increasing episode dura-
tion, and particularly poor interepisodic recovery (Depression 
Guideline Panel 1993; Thase and Rush 1995). Treatment for 
this population needs to be aimed at producing full remis-
sion since anything short of remission is likely to result in 
relapse, recurrence, and future treatment resistance. The fact 
that 60%–70% of all patients with MDD meet criteria for 
TRD underscores the need for systematic development of 
innovative treatments for TRD (Insel 2006; Rubinow 2006). 
Currently, available clinical options after an initial optimal 
antidepressant trial (ie, at adequate doses and of sufﬁ  cient 
duration) include switching to another antidepressant, as well 
as combination and augmentation strategies where another 
agent is added to the original antidepressant.
Adjunctive antipsychotics in the 
treatment of major depressive 
disorder
Phenothiazine antipsychotics have been shown to be effec-
tive in the treatment of nonpsychotic affective disorders 
(Schatzberg and Nemeroff 2006). However the high inci-
dence of extrapyramidal side effects associated with these 
agents (especially in patients with mood disorder) has limited 
their use in this patient population. With the availability of 
the atypical antipsychotics, the risk of extrapyramidal side 
effects is now considerably reduced. Atypical antipsychotics 
have been shown to be an effective treatment for depressive 
symptoms associated with schizophrenia, bipolar disorder, 
posttraumatic stress disorder, and anxiety disorder in post-
hoc analyses from several studies (Tollefson et al 1998; 
Vieta et al 2001; Nemeroff et al 2002). In addition, clinical 
guidelines currently recommend atypical antipsychotics 
combined with antidepressants as ﬁ  rst-line treatment for 
psychotic depression (Kennedy et al 2001).
In addition to widespread clinical use of atypical anti-
psychotics, there is now accumulating evidence that atypical 
antipsychotics may have a role to play in the treatment of 
patients with TRD (Hirschfeld et al 2002; Nemeroff 2005; 
Papakostas et al 2007). Preclinical studies have shown that 
the atypical antipsychotics risperidone and olanzapine have 
5-HT2A antagonist effects, which may enhance the action of 
serotonin, and therefore augment the therapeutic effect of the 
selective serotonin reuptake inhibitors (SSRIs) (Ostroff and 
Nelson 1999; Pitchot and Ansseau 2001; Shelton et al 2001). 
In addition, animal studies have shown that the combination 
of SSRIs and atypical antipsychotics has synergistic effects 
on the release of dopamine and norepinephrine (Tarazi et al 
2002). It has been suggested that prefrontal cortical activation 
may have salutary effects on mood (Hirschfeld et al 2002). 
Two atypical antipsychotics, clozapine and olanzapine, have 
been shown to increase dopamine release in the prefrontal 
cortex, whereas haloperidol (a conventional antipsychotic) 
does not (Tarazi et al 2002). Another atypical antipsychotic, 
risperidone, has also been found to have a more modest effect 
on norepinephrine and dopamine release in the prefrontal 
cortex.
Until recently, there had been few randomized controlled 
trials (RCTs) looking at the atypical antipsychotics as an 
augmentation strategy for TRD, with those that had been 
done presenting conﬂ  icting results (Papakostas et al 2007). 
However, there is preliminary evidence that risperidone 
may be effective as an adjunctive agent when combined 
with an antidepressant (O’Connor and Silver 1998; Ostroff 
and Nelson 1999; Hirose and Ashby 2002; Viner et al 2003; 
Nemeroff et al 2004). Similarly, there is also evidence from 
double-blind trials that augmentation of ﬂ  uoxetine with 
olanzapine produces signiﬁ  cantly greater improvement in 
depression compared with either olanzapine or ﬂ  uoxetine 
monotherapy (Shelton et al 2001; Dube et al 2002). How-
ever, in two recently published large RCTs, by the end 
of the studies the authors found no signiﬁ  cant difference 
between treatment with the ﬂ  uoxetine and olanzapine com-
bination (OFC) compared to either olanzapine or ﬂ  uoxetine 
monotherapy, and nortriptyline (Shelton et al 2005) or ven-
lafaxine (Corya et al 2006). It should be noted that in post 
hoc analysis conducted in the subgroup of patients who had 
failed an adequate selective serotonin reuptake inhibitor 
(SSRI) trial in the current major depressive episode, OFC 
showed a statistically signiﬁ  cant difference at endpoint in 
one study compared to the olanzapine group (Shelton et al 
2005) and in the second study (Corya et al 2006), a statistical 
difference was seen between the OFC and either olanzapine 
or ﬂ  uoxetine monotherapy. Similarly, recently, Thase and 
colleagues (Thase et al 2007), found that OFC demonstrated 
signiﬁ  cantly greater improvement in depressive symptoms 
compared olanzapine monotherapy in one of two studies 
and in a pooled analysis of patients with TRD. To date, 
other open label studies with both ziprasidone (Dunner et al Neuropsychiatric Disease and Treatment 2007:3(6) 857
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2003; Papakostas et al 2004) and aripiprazole (Papakostas 
et al 2005; Simon and Nemeroff 2005) suggest both agents 
to be effective when used as adjunctive treatments to an 
antidepressant.
In a recent meta-analysis of 10 RCTs assessing adjunc-
tive treatment of a standard antidepressant with an atypical 
antipsychotic agent (olanzapine, risperidone, or quetiapine), 
Papakostas et al found that patients randomized to adjunctive 
treatment with an atypical antipsychotic were more likely to 
experience remission or clinical response compared to those 
who received adjunctive placebo, with pooled remission and 
response rates for both groups 47.4% vs 22.3% and 57.2% 
vs 35.4%, respectively (Papakostas et al 2007). Though 
requiring further investigation in terms of efﬁ  cacy, safety, 
and tolerability as compared to other adjunctive strategies, 
all of the above data suggest that atypical antipsychotic 
augmentation of antidepressants may be a viable option for 
patients with TRD.
Quetiapine
Pharmacological properties
Quetiapine (Seroquel) was approved by the US Food and 
Drug Administration (FDA) in 1997 and is an atypical 
antipsychotic with established efﬁ  cacy in the treatment of 
schizophrenia (Cheer and Wagstaff 2004). The preclinical 
proﬁ  le of quetiapine is similar to the ﬁ  rst atypical antipsy-
chotic, clozapine, but with a reduced tendency to cause motor 
disturbances (Nemeroff et al 2002). Quetiapine is a diben-
zothiazepine derivative for which the mechanism of action 
is unknown. It acts as an antagonist at serotonin 5-HT1A and 
5-HT2A, dopamine D1 and D2, histamine H1 and adrenergic 
α1 and α2 receptors (Dando and Keating 2005). Of note, it 
has a much higher level of occupancy of 5-HT2A receptors 
compared to D2 receptors, a factor generally considered to 
be predictive of an atypical antipsychotic (Goldstein 1996). 
Quetiapine has negligible afﬁ  nity for cholinergic muscarinic 
receptors, thereby contributing to its low risk for anticholin-
ergic side effects. There is also evidence from animal models 
of low potential for extrapyramidal side effects (Cheer and 
Wagstaff 2004).
In terms of pharmacokinetics, the absorption of quetiap-
ine is rapid, with the median time to maximum observed 
plasma concentration ranging from 1 to 2 hours (DeVane 
and Nemeroff 2001). Quetiapine is approximately 83% 
protein-bound, with a mean terminal half-life reported as 
approximately 7 hours. It is metabolized primarily in the 
liver, mainly by sulphoxidation by cytochrome P450 (CYP) 
3A4 (Grimm et al 1997). Although, quetiapine neither 
induces nor inhibits CYP 3A4, caution is required when 
administering quetiapine with other drugs, which inhibit 
or induce the CYP 3A4 isoenzyme (DeVane and Nemeroff 
2001). Quetiapine doses for the treatment of psychosis range 
from 150 mg to 750 mg/day.
Quetiapine in the treatment 
of depressive symptoms in schizophrenia
Mood disorders in patients with schizophrenia are associated 
with poor outcome, an increased risk of relapse, and a high 
rate of suicide (Meltzer et al 1998). It is estimated that the 
prevalence of syndromal depression in schizophrenia ranges 
from 25% to 60% (Martin et al 1985; Johnson 1988; Hirsch 
and Jolley 1989; Harrow et al 1994). There is evidence to 
date suggesting a positive effect associated with the atypical 
antipsychotics in patients with schizophrenia who experience 
depression (Muller-Siecheneder et al 1998; Tollefson et al 
1998; Keck et al 2000). In terms of quetiapine, one group 
looked at data from two double blind, placebo-controlled, 
acute, 6-week trials evaluating the effects of quetiapine on 
depressive signs and symptoms in patients with schizophre-
nia (Arvanitis et al 1997). Data from both trials showed that 
quetiapine was superior to placebo in improving depressive 
symptoms, whereas haloperidol (used as a comparator) was 
not (Arvanitis et al 1997). Similarly, there is evidence sup-
porting the maintenance of the efﬁ  cacy of quetiapine in the 
treatment of depressive and anxiety symptoms in schizophre-
nia with long-term treatment (Kasper 2004).
Quetiapine in the treatment of bipolar 
depression
Bipolar depression is a recurrent and extremely debilitat-
ing phase of bipolar disorder, with patients with bipolar 
disorder overall experiencing more depressive symptoms 
than either mania or hypomania. The neurochemistry and 
pathogenesis of bipolar disorder remain poorly understood. 
In terms of treatment options, there is some evidence to date 
suggesting that treating bipolar depression with antidepres-
sants alone may be associated with a possible increased 
risk of treatment-emergent mania (Grunze 2005). Currently 
lithium and lamotrigine are recommended as initial treat-
ments for acute bipolar I depression (Hirschfeld et al 2002; 
Goodwin and Consensus Group of the British Association 
of Psychopharmacology 2003); however, the response rate 
rarely exceeds 50%.
More recently, there is evidence of the efﬁ  cacy of the 
atypical antipsychotics in the treatment of bipolar depression 
(Tohen et al 2003; Calabrese et al 2005). Like the olanzapine/Neuropsychiatric Disease and Treatment 2007:3(6) 858
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fluoxetine combination, quetiapine has recently been 
approved for this indication. The efﬁ  cacy of oral quetiapine 
has been assessed in two recent positive, placebo-controlled 
trials demonstrating efﬁ  cacy in the acute treatment of bipolar 
depression (Calabrese et al 2005; Thase et al 2006), as well 
as several other open-label trials (Sajatovic et al 2001; Milev 
et al 2006). Similarly, pooled data from the two placebo-
controlled studies discussed above (Calabrese et al 2005; 
Thase et al 2006) show evidence supporting the efﬁ  cacy of 
quetiapine monotherapy (either 300 mg or 600 mg/day) in 
patients with bipolar II disorder (Hirschfeld et al 2006).
Looking at the potential mechanism of action in bipolar 
depression, animal studies have shown that atypical anti-
psychotics such as quetiapine that block 5-HT2A receptors 
down-regulate brain 5-HT2A receptors (Tarazi et al 2002). It 
is suggested that down-regulation of 5HT2A seems to repre-
sent a strong point of commonality between quetiapine and 
antidepressant treatments (Yatham et al 2005). In addition, 
concomitant dampening by quetiapine of dopamine signaling 
in the mesolimbic pathways may be advantageous in prevent-
ing the dopamine-induced switching to hypomania that can 
occur with unimodal antidepressants (Yatham et al 2005).
Quetiapine for major depression 
with psychotic features
In terms of MDD with psychotic features, though there have 
been reports of quetiapine in the treatment of a variety of 
psychotic disorders (Zarate et al 2000; Sajatovic et al 2002), 
at the time of writing we are only aware of one 6-week, open 
label multi-center study looking at adjunctive quetiapine 
patients with unipolar depression with psychotic features 
(Konstantinidis et al 2007). This small study evaluated the 
efﬁ  cacy of quetiapine in combination with citalopram in 
adults (n = 25) with DSM-IV diagnosis of unipolar psychotic 
depression. The primary endpoint assessed was change 
from baseline in HAM-D-21. The authors report that mean 
HAM-D was reduced from 31.21 ± 5.18 at baseline to 13.25 ± 
10.87 at week 6 (p   0.05). In addition, signiﬁ  cant improve-
ment was also seen in psychotic symptoms as indicated by a 
decrease in the Brief Psychiatric Rating Scale (BPRS) from 
59.25 ± 6.60 to 35.25 ± 15.60 at week 6 (p   0.001).
Quetiapine as an adjunctive 
treatment for major depressive 
disorder
As mentioned earlier, the fact that 60%–70% of all patients 
with MDD meet criteria for TRD underscores the need for 
systematic development of innovative treatments for TRD 
(Insel 2006; Rubinow 2006). While there is accumulating 
evidence supporting the strategy of antidepressant augmen-
tation with atypical antipsychotics (Hirschfeld et al 2002; 
Nemeroff 2005; Papakostas et al 2007), the efﬁ  cacy of this 
treatment strategy has not yet been ﬁ  rmly established. In view 
of the importance of further evaluating the potential role of 
atypicals in MDD and the large number of just completed 
trials, we will describe ﬁ  rst the published literature for ran-
domized controlled trials (RCTs), open label trials, as well as 
case series, and follow that up with the review conducted on 
poster presentations since a large number of RCTs are not yet 
published. We are only aware of two published randomized, 
controlled trials evaluating quetiapine in treatment-resistant 
depression (Yargic et al 2004; Hussain et al 2005), with 
further results from several other studies presented at recent 
meetings (Mattingly et al 2006; McIntyre et al 2006).
In their prospective, single-blind trial, Yargic and col-
leagues reported on patients with a DSM-IV diagnosis of 
MDD and associated anxiety who were randomly assigned 
to an 8-week treatment with paroxetine alone (n = 54) or 
paroxetine plus quetiapine (n = 58) (Yargic et al 2004). 
Quetiapine was given at a dose of up to 200 mg/day and 
paroxetine at a dose of up to 60 mg/day. The authors found 
that decrease in HAM-D scores were signiﬁ  cantly greater 
in the combined therapy group than with paroxetine alone 
throughout the study period (p   0.008). In addition, in terms 
of associated anxiety, the decrease in Hamilton Anxiety 
Rating Scale (HAM-A) scores was also signiﬁ  cantly greater 
in the combined therapy group compared to paroxetine alone 
at weeks 2, 4, 6, and LOCF (p   0.008).
Similarly, in their study, Hussain and colleagues con-
ducted a randomized, double-blind study in 72 patients with 
MDD comparing the efﬁ  cacy of monotherapy antidepressant 
treatment with an SSRI or a Serotonergic Noradrenergic 
Reuptake Inhibitor (SNRI), compared to adjunctive quetiap-
ine therapy in the treatment of MDD and in the maintenance 
of remission of symptoms (Hussain et al 2005). Patients were 
randomly assigned to one of four treatment groups: parox-
etine monotherapy, venlafaxine monotherapy, paroxetine 
and quetiapine combination, or venlafaxine and quetiapine 
combination. Scores from the 17-item HAM-D were assessed 
at baseline, weeks 1, 3, 6, and 12, and every 6 months for 
3 years. Improvement in and maintenance of HAM-D17 scores 
were seen in all four groups at week 3 and maintained at 
assessments over the 3-year study. Signiﬁ  cant improvement 
in depressive symptoms and the development of remission 
occurred more frequently in the paroxetine and quetiapine Neuropsychiatric Disease and Treatment 2007:3(6) 859
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combination group. However, a greater overall frequency of 
adverse events was also observed in the combination therapy 
groups vs the monotherapy groups.
There is also preliminary evidence from open-label stud-
ies (Vavrusova 2002; Adson et al 2004; Sagud et al 2006; 
Baune et al 2007; Doree et al 2007) and case reports (Pathak 
et al 2005; Devarajan et al 2006) supporting the potential 
beneﬁ  ts of quetiapine in this area (see Table 1). In a recent 
publication, Doree and colleagues report on an 8-week, 
open-label, pilot study in which they compared the effects 
of quetiapine and lithium when used as an adjunct to anti-
depressant medication in 20 patients with MDD (Doree et al 
2007). Prior to commencing adjunctive treatment with either 
agent, participants had a HAM-D score   20 after 4 weeks at 
maximal antidepressant dose. Lithium was initiated at a dose 
of 600 mg/day and adjusted in time to achieve blood levels 
between 0.8–1.2 nmol/L. Quetiapine was titrated to a maxi-
mum of 400 mg/day in the ﬁ  rst week and then to a maximum 
of 800 mg/day as clinically indicated. Outcome measures 
included difference in HAM-D and Montgomery Asberg 
Depression Rating Scale (MADRS) from baseline to week 8. 
Data from 20 patients were analyzed (10 on lithium, 10 on 
quetiapine). Results showed that depression, measured by the 
HAM-D signiﬁ  cantly improved from baseline in both que-
tiapine (F1,90 = 25.11, p   0.0001) and lithium (F1,90 = 34.54, 
p   0.0001), with a difference in improvement between the 
two groups (in favor of quetiapine) seen at day 14, and present 
at all time points thereafter (p   0.05). Similarly, signiﬁ  cant 
improvement was seen on the MADRS in both the quetiapine 
group (F1,90 = 68.89, p   0.0001) and lithium (F1,90 = 35.11, 
p   0.0001), with a signiﬁ  cant difference in improvement 
in favor of quetiapine seen at week 4 (p   0.05). Evaluation 
on the HAM-D showed a response rate of 80% and 50% for 
quetiapine and lithium respectively, with a remission rate of 
80% and 40%. Similarly, on the MADRS the response rate 
was 80% and 50%, and the remission rate was 80% and 30% 
for quetiapine and lithium respectively (see Table 1).
In another recently published, small, open-label, non-
comparative, ﬂ  exible-dosed, 20-week study evaluated the 
effects of quetiapine as an add-on therapy in patients with 
TRD who were refractory to previous treatments (Sagud et al 
2006). The mean dose of quetiapine during the 20-week trial 
was 515 ± 109 mg/day. Patients were evaluated at different 
points in time throughout the study with the HAM-D rating 
scale. Of the 18 patients enrolled in the study at baseline, 
14 patients completed the open-label study. After the fourth 
week of treatment, results showed that augmentation with 
quetiapine signiﬁ  cantly reduced HAM-D total scores, as well 
as scores on the HAM-A anxiety subscale. After the ﬁ  fth 
week of treatment, scores on the HAM-D depressed mood 
subscale were also signiﬁ  cantly reduced. Quetiapine add-
on therapy was also associated with a signiﬁ  cant decrease 
in the HAM-D insomnia subscale after the second week of 
treatment (Sagud et al 2006).
In an earlier open-label pilot study, Vavrusova also 
reported on a trial of adjunctive quetiapine (n = 13) or adjunc-
tive haloperidol (n = 13) in patients with severe, nonpsychotic 
depression not responding to 4 weeks of treatment with 
citalopram (Vavrusova 2002). Outcome measures included 
the HAM-D, the HAM-A, and the Positive and Negative 
Syndrome Scale (PANSS). At a dose of 200 mg/day, quetiap-
ine was found to signiﬁ  cantly improve levels of depression, 
suicidal ideation, and retardation, as well as improving 
anxiety and sleep compared to haloperidol.
Another recently published 4-week open label study 
looked at clinical outcomes, quality of sleep and daytime 
motor activity in patients with treatment resistant major 
depression (n = 21) or bipolar depression (n = 6) who 
received a standard antidepressant (venlafaxine, escitalo-
pram) plus a ﬂ  exible dose of quetiapine (Baune et al 2007). 
Daily doses of quetiapine ranged between 300mg/day up to 
a maximum of 800 mg/day over the 4 week study. Outcome 
measures included the HAM-D-21, the Pittsburgh Sleep 
Quality Index (PSQI), with motor activity continuously 
measured by actigraphy. At admission, the HAM-D-21 score 
was 20.2 (SD ± 6.8), and after treatment it was 9.4 (SD ± 
4.8), and 4.9 (SD ± 3.2) at discharge (p   0.001). It should 
be noted that all open label studies cited above were of small 
sample size and lacked a control group.
Further evidence suggesting the potential of quetiapine as 
an augmentation agent for TRD comes from a recent natural-
istic case series, in which the authors present outcomes for 
six consecutive patients with nonpsychotic TRD – treated 
with the combination of sertraline (SSRI) and quetiapine 
(Devarajan et al 2006). All patients initially received sertra-
line monotherapy and then commenced adjunctive quetiapine 
after 6 or 8 weeks because of lack of signiﬁ  cant clinical 
effect. Results showed that sertraline had minimal effect on 
baseline 21-item HAM-D scores; however, adding quetiap-
ine improved ratings and outcomes at week 5–6 (Devarajan 
et al 2006). The authors suggest that the effectiveness of the 
combination of the SSRI antidepressant and quetiapine may 
result from the targeting of multiple neurotransmitters/recep-
tors and speciﬁ  c mood-modulating neuroanatomical regions 
of interest. Additionally, they speculate that improvement 
in quality of sleep may have contributed to the improved Neuropsychiatric Disease and Treatment 2007:3(6) 860
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mental well-being of patients treated with add-on quetiapine 
(Devarajan et al 2006).
There is also preliminary evidence for use of quetiapine 
as an adjunctive treatment for treatment-resistant adolescent 
MDD (Pathak et al 2005). In a recently published case series, 
Pathak et al report on the use of adjunctive quetiapine in 
10 adolescents with MDD who had failed to respond to a 
prior trial of SSRI of at least 8 weeks duration (Pathak et al 
2005). Seven of 10 subjects (70%) showed much or very 
much improved on clinical global improvement (CGI) rat-
ing scale (ie, score 1 or 2). The median dose of quetiapine 
prescribed was 200 mg (mean ± SD = 275 ± 190.4 mg; range 
150–800 mg). Side effects included sedation (40%) and 
weight gain (mean ± SD = 4.5 ± 7.24 pounds). The authors 
noted that the associated weight gain seen with quetiapine 
in this case series should be taken into consideration while 
calculating the risk-benefit ratio in the management of 
treatment-resistant depression in this patient population. No 
serious adverse events were reported.
In addition to the studies and case reports cited above, 
there are currently eight double blind, placebo-controlled 
studies ongoing at present looking at quetiapine either as a 
monotherapy or as an augmentation agent in the treatment 
of major depressive disorder (see http://www.clinicaltrials.
gov).
Randomized trials of quetiapine 
presented as posters
In a recent poster presentation, McIntryre and colleagues 
presented data from a double-blind, randomized, placebo-
controlled study in 58 patients, which evaluated the use 
of quetiapine as an adjunctive treatment to either SSRIs 
or SNRIs for patients with MDD associated with residual 
depressive and prominent anxiety symptoms (McIntyre et al 
2006). Prior to receiving adjunctive treatment, study partici-
pants had received at least 6 weeks of SSRI/SNRI treatment, 
and were then randomly assigned to receive adjunctive que-
tiapine (n = 29) or adjunctive placebo (n = 29). Quetiapine 
was gradually titrated up to a maximum of 600 mg/day as 
clinically indicated. The mean dose of quetiapine was 182 ± 
69 mg/day. The primary outcome was mean change from 
baseline to week 8 in HAM-D and HAM-A scores (last 
observation carried forward [LOCF] analysis). Results: 
18/29 quetiapine-treated patients and 16/29 placebo-treated 
patients completed the study. Signiﬁ  cant improvement from 
baseline was seen in the HAM-D score at week 1 (−6.5 vs −2.9; 
p   0.01) and at week 8 (−11.2 vs –5.5; p   0.01) in the que-
tiapine vs placebo group, respectively. HAM-D response rates 
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(48% vs 28%) and remission rates (31% vs 17%) were also 
higher in the quetiapine group compared to placebo.
Similarly, Mattingly et al recently presented a poster 
documenting their ﬁ  ndings from an 8-week, double-blind, 
randomized, placebo-controlled trial evaluating the efﬁ  cacy 
of adjunctive quetiapine in depressed patients who were 
partial responders to at least 6 weeks of SSRI/SNRI treat-
ment (Mattingly et al 2006). In this study patients with a 
baseline HAM-D   20 were randomly assigned to receive 
either adjunctive quetiapine 200–400 mg/day (n = 23) or 
placebo (n = 13), with randomization occurring in a 2:1 ratio 
in favor of quetiapine. The primary outcome measure was 
change in HAM-D score from baseline to week 8. The inves-
tigators found that HAM-D scores signiﬁ  cantly improved 
from baseline (25.0 vs 24.5) to endpoint (8.3 vs 14.7) in 
the quetiapine vs placebo groups, respectively (p   0.01). 
Similarly, MADRS scores improved from baseline (32.4 vs. 
33.5) to endpoint (15.4 vs 24.8) in the quetiapine vs. placebo 
groups, respectively (p   0.05). Of note, the authors report 
that they used a paired t-test and LOCF as the statistical 
approach for this analysis. Speciﬁ  cally, more patients were 
responders (67% vs 27%, p = 0.015) or remitters (43% vs 
15%, p   0.05) in the quetiapine group compared to the 
placebo group (see Table 2).
Finally, in yet another poster presentation, Khullar et al 
present data from a small, double blind trial comparing 
adjunctive quetiapine to placebo in 16 patients who had 
failed a 6-week trial of adequate doses of an SSRI or SNRI 
(Khullar et al 2006). The average dose of quetiapine used 
was 350 mg/day. An LOCF analysis using independent 
samples t-tests showed signiﬁ  cantly greater (p   0.05) mean 
changes in the HAM-D17, MADRS, and HAM-A for the 
quetiapine group (n = 8) versus the placebo group (n = 7). 
One limitation of this study is the small sample size.
Quetiapine as a treatment for anxiety 
symptoms associated with MDD
One recent 4-week, open label study evaluated the anxiolytic, 
antidepressive, and sleep effects and safety of quetiapine 
in patients with MDD who were on stable doses of SSRIs 
and presented with persistent anxiety (Targum et al 2005). 
Prior to entry into the study, eligible patients had been tak-
ing either an SSRI or SNRI for at least 6 weeks, and had a 
HAM-A   20 and a HAM-D   17 at screening and baseline. 
A total of 17 patients completed the study. Mean quetiapine 
doses achieved were 105 ± 65.6 mg/day. Results at endpoint 
showed signiﬁ  cant improvement in HAM-A scores (25.6 ± 
5.5 baseline to 9.2 ± 5.5); p   0.001). The HAM-D score also 
improved from 15 ± 1.8 at baseline to 7.2 ± 5.0 at endpoint 
(p   0.001).
Similarly, in their 9-week, open-label, ﬂ  exible-dosed 
study, Adson and colleagues assessed quetiapine as an 
adjunctive therapy for SSRIs in 11 patients with either 
anxiety symptoms complicating a depressive disorder or 
an anxiety disorder (Adson et al 2004). Of the 11 patients 
participating in the study, 6 had a diagnosis of MDD with 
a comorbid anxiety disorder. To be eligible for the 9-week, 
open-label, ﬂ  exible-dosed study, patients had to be currently 
treated with an SSRI at an adequate dose for at least 6 weeks. 
Quetiapine was titrated gradually based on tolerability and 
effect during the ﬁ  rst 3 weeks up to a maximum total daily 
dose of 300 mg (100 mg qam and 200 mg qhs). A total of 
10 patients completed the study. Clinically relevant reduc-
tions in mean HAM-D, HAM-A, and the State Anxiety Index 
(SAI) scores from baseline were seen as early as week 1, with 
sustained improvement in symptoms on all three measures 
over the 9-week period. HAM-D scores decreased from a 
mean of 20.27 to 5.64 at the ﬁ  nal visit, while HAM-A scores 
decreased from a mean of 24.45 at baseline to 5.82 at study 
completion (Adson et al 2004) (see Table 1).
There is also evidence from case series supporting que-
tiapine as a monotherapy in MDD and comorbid anxiety 
disorder. In one case series of 36 patients with a DSM–IV 
diagnosis of generalized anxiety disorder (GAD) (22 patients) 
or GAD with panic disorder (14 patients), 27 suffered 
from comorbid MDD (Galynker et al 2005). Patients were 
treated with either risperidone (n = 23) or quetiapine (n = 
13). Risperidone was commenced at a total daily dose of 
0.125 mg/day and gradually titrated to a maximum dose of 
0.5 mg/day. Patients on quetiapine started on a total daily 
dose of 25 mg/day and gradually were titrated to a maximum 
of 300 mg/day. Outcomes were assessed with the HAM-A 
and modiﬁ  ed HAM-D (with two anxiety items removed). 
A total of 32 patients completed the study. Mean baseline 
HAM-D scores were 24.95 ± 10.01 and 20.31 ± 7.79 for 
patients receiving risperidone or quetiapine, respectively. 
Mean posttreatment HAM-D scores were 6.37 ± 4.96 (p   
0.001) and 12.15 ± 5.44 (p   0.001) for patients treated 
with risperidone or quetiapine, respectively. Mean baseline 
HAM-A scores were 21.42 ± 5.53 for patients treated with 
risperidone and 24.92 ± 6.45 for patients treated with quetiap-
ine. Mean posttreatment HAM-A scores were 5.68 ± 5.03 for 
patients treated with risperidone and 7.46 ± 5.71 for patients 
treated with quetiapine. Speciﬁ  cally, of the 13 patients tak-
ing quetiapine, 10 (77%) demonstrated an improvement in 
HAM-A scores by at least 50%, with 4 (31%) demonstrating Neuropsychiatric Disease and Treatment 2007:3(6) 863
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improvement in HAM-D scores by at least 50% (Galynker 
et al 2005). The mean daily dosages of risperidone and que-
tiapine were 0.21 ± 0.11 mg and 105.8 ± mg, respectively.
Tolerability and safety proﬁ  le
Studies to date (mainly in schizophrenia) have demonstrated 
a low propensity of quetiapine to produce extrapyramidal 
side effects (EPS) or elevated prolactin levels (Kapur et al 
2002; Lieberman and Perkins 2002). Extrapyramidal side 
effects include akathisia, dystonia, and Parkinsonism. In vivo 
functional studies with quetiapine all provide evidence that 
quetiapine has a preferential effect on limbic as opposed to 
striatal D2 receptors (Nemeroff et al 2002). Extrapyramidal 
side effects are associated with D2 occupancy in the striatum, 
therefore predicting low levels of EPS for quetiapine. Simi-
larly, unlike olanzapine and risperidone, the lack of effect of 
quetiapine on dopamine receptors in vitro studies in the basal 
ganglia provides further evidence to suggest low levels of 
EPS with quetiapine (Tarazi et al 2001). Finally, it has been 
suggested that because quetiapine is loosely bound to D2 
receptors, its rapid release from D2 receptors may contribute 
to their low D2 occupancy and lower potential to cause EPS 
(Seeman and Tallerico 1998).
Prolactin elevation appears to be associated with the 
blockade of D2 receptors at the level of the anterior pituitary 
lactotrophs, where dopamine exerts an inhibitory effect on 
prolactin secretion (Jaber et al 1996). Unlike the striatum, the 
anterior pituitary lies outside the blood-brain barrier. In terms 
of atypical antipsychotics, compounds displaying a higher 
peripheral potency have been shown to bring about higher 
prolactin levels for a given level of functional central antago-
nism (Kapur et al 2002). In contrast, quetiapine has been 
shown in animal studies to have a relatively low differential 
occupancy of D2 receptors in the striatum compared versus 
the pituitary, thereby further explaining its low propensity to 
cause hyperprolactinemia (Kapur et al 2002).
Most of the existing data regarding the safety and tol-
erability of quetiapine relates to its use in patients with 
schizophrenia, however there is preliminary data emerging 
from studies looking at quetiapine in affective disorders. 
Data concerning tolerability of quetiapine in patients with 
bipolar depression is now available from the BOLDER 
I and II trials (Calabrese et al 2005; Thase et al 2006), 
with evidence that quetiapine is generally well tolerated 
in patients with bipolar depression (Keating and Robinson 
2007). Across both studies EPS was reported in 6.7% and 
12.3% of those receiving quetiapine 300 mg/day, 8.9% and 
10.1% of those receiving the 600 mg/day dose, and 2.2% 
and 6.6% of those receiving placebo (Calabrese et al 2005; 
Thase et al 2006). No clinically signiﬁ  cant differences were 
seen across treatment groups in terms of vital signs, ECG 
readings, or laboratory parameters. Of note, there was no 
signiﬁ  cant difference in the incidence of treatment-emergent 
mania between quetiapine and placebo in either study.
Another factor to evaluate when considering using 
adjunctive quetiapine for MDD is the issue of weight gain. In 
a recent review article, Gentile reviews the risk of weight gain 
associated with long-term treatment with atypical antipsy-
chotics (Gentile 2006). Previous analyses of weight changes 
in patients participating in trials of quetiapine (controlled, 
uncontrolled, and open label-extensions) suggest that the 
risk for quetiapine-induced weight-gain is not dose-related. 
According to Gentile’s review, however, there is conﬂ  icting 
data regarding weight gain associated with quetiapine, with 
some studies showing only modest weight gain (Kasper and 
Muller-Spahn 2000; Brecher et al 2004; Nagy 2005), and oth-
ers reporting clinically relevant weight gain (McIntyre et al 
2003; Sprague et al 2004). The author reports that in short-
term studies, a deﬁ  nite rank order of weight-gain potential 
among atypical antipsychotic has been demonstrated with 
clozapine related to the highest risk of weight gain, followed 
in decreasing order of magnitude by olanzapine, quetiapine, 
risperidone, amisulpride, aripiprazole, and ziprasidone. In 
contrast, in long-term studies, apart from clozapine at one end 
of the spectrum and ziprasidone at the other, the difference 
in weight gain shown by the other atypical antipsychotics 
became less intense (Gentile 2006).
The recent BOLDER I and II studies report a mean 
weight gain of 1.0 and 1.4 kg with quetiapine 300 mg/day, 
1.6 and 1.3 kg with the 600 mg/day dose, compared to 0.2 
and 0.3 kg with placebo (Calabrese et al 2005; Thase et al 
2006). To date there is little information available in terms 
of major depressive disorder, however, a recent study cited 
earlier, looking at MDD with psychotic features reported an 
average weight change of +2.1 kg (±SD), with mean weight 
at visit 1, 72.72 (±16.34) kg and mean weight at visit 4, 74.79 
(±18.69) kg (Konstantinidis et al 2007).
Discussion
Treatment-resistant major depressive disorder is a common 
problem in clinical practice and often poses a considerable 
challenge to the treating physician. Prior studies suggest 
that atypical antipsychotics have a role to play in the treat-
ment of treatment-resistant MDD (Hirschfeld et al 2002). 
From our review of the literature above, we found growing 
evidence speciﬁ  cally supporting the use of quetiapine as an Neuropsychiatric Disease and Treatment 2007:3(6) 865
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adjunctive agent in patients with TRD, particularly in patients 
with residual symptoms of anxiety and sleep difﬁ  culties. 
Unfortunately, few randomized controlled trials are available 
through peer-reviewed publications.
As an atypical antipsychotic with a low propensity to 
cause either extrapyramidal side effects or hyperprolac-
tinemia, quetiapine has been shown to be a potential treatment 
in a broad range of psychiatric disorders (Adityanjee and 
Schulz 2002). Speciﬁ  cally, in terms of depressive symp-
toms, we see that there is accumulating evidence support-
ing the beneﬁ  ts of quetiapine as an adjunctive treatment in 
TRD as well as bipolar depression. Even though the exact 
mechanism of action is not known, it appears to relate to the 
5-HT2A antagonist effects, which may enhance the action of 
serotonin, and therefore augment the therapeutic effect of the 
selective serotonin reuptake inhibitors (SSRIs). Similarly, 
animal studies have shown that the combination of SSRIs and 
atypical antipsychotics has synergistic effects on the release 
of dopamine and norepinephrine (Tarazi et al 2002).
To date, there are only a few randomized trials looking 
at adjunctive quetiapine in the treatment of major depressive 
disorder. Given the prevalence of treatment resistance in this 
disorder, as well as the evidence from studies to date, further 
placebo-controlled trials are indicated at this time. In addition 
to efﬁ  cacy, the potential for weight gain associated with the 
use of atypical antipsychotics is also an issue for clinicians to 
consider in their clinical decision-making. Overall, however, 
preliminary evidence suggests that quetiapine may be an 
effective treatment to be added to our current armamentarium 
of options for this patient population.
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